Key terms
About EDSA
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), EB02 for hemorrhoids, and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest EDSA news
Apr 11
4:37pm ET
Edesa Biotech Showcases Innovation at Investor Conference
Apr 02
9:38am ET
Edesa Biotech Engages Investors at Global Conferences
Mar 22
12:37am ET
Edesa Biotech Shines at Autoimmune Conference
Mar 07
4:07pm ET
Edesa Biotech Showcases Innovations at Healthcare Conference
Mar 04
11:07pm ET
Edesa Biotech Showcases Innovations at Dermatology Events
No recent press releases are available for EDSA
EDSA Financials
Key terms
Ad Feedback
EDSA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
EDSA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
